A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors
Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P180
Published Online: 2015-11-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hecht, J Randolph
Raman, Steven
Sze, Daniel Y
Lockhart, A Craig
Moss, Rebecca A
Liu, Kate
Chou, Jeffrey
Reid, Tony
Article History
First Online: 4 November 2015